U.S. markets open in 5 hours 39 minutes

NantHealth, Inc. (NH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5800-0.0300 (-1.15%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close2.6100
Open2.7600
Bid0.0000 x 2200
Ask0.0000 x 1800
Day's Range2.5400 - 2.7700
52 Week Range1.9000 - 6.6000
Volume1,087,046
Avg. Volume526,717
Market Cap287.203M
Beta (5Y Monthly)1.69
PE Ratio (TTM)N/A
EPS (TTM)-0.5120
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • NantHealth Announces $137.5 Million New Financing With Highbridge Capital Management and Nant Capital
      Business Wire

      NantHealth Announces $137.5 Million New Financing With Highbridge Capital Management and Nant Capital

      NantHealth, Inc. (NASDAQ-GS: NH), a provider of enterprise solutions that help transform complex data into actionable insights, today announced the signing of a new financing that will include the issuance of $137.5 million aggregate principal amount of new senior unsecured convertible notes due 2026 (the "2026 Notes") in a private transaction, with the common stock that may be issued upon a conversion to be registered under the Securities Act of 1933, as amended (the "Securities Act"). As part of the transaction, the company will enter into an agreement to extend the maturity of its existing subordinated note to October 2026. The company intends to use the proceeds of the 2026 Notes to retire its existing convertible notes due December 2021 (the "2021 Notes") and further invest in initiatives to grow its business.

    • NantHealth Unveils Population Health Management Tools to Help Payers and Providers Deliver on Value-Based Care Initiatives
      Business Wire

      NantHealth Unveils Population Health Management Tools to Help Payers and Providers Deliver on Value-Based Care Initiatives

      NantHealth, Inc. (NASDAQ: NH), today announced a new population health management product that pulls together disparate data to provide a full 360-degree picture of the patient while enabling better workflow between providers, payers, hospitals/healthcare networks and patients in one platform. This new product reduces avoidable costs and increases patient and provider satisfaction.

    • 'Unless we vaccinate the entire planet, we won't get rid of this pandemic:' Vaccine developer
      Yahoo Finance

      'Unless we vaccinate the entire planet, we won't get rid of this pandemic:' Vaccine developer

      Controversial billionaire scientist Dr. Patrick Soon-Shiong discusses COVID-19 vaccine efforts.